bone morphogenetic protein 6Genealiases: IO · VGR · VGR1
Q-omics provides the consensus-scored BMP6 profile across patient tissues and cancer cell-line models. BMP6 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, BMP6 is differentially expressed in 13, with the highest sampling consensus in KICH. Additionally, BMP6 RNA expression shows 17,920 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, KICH, and THYM as cancer lineages where BMP6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for BMP6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes BMP6 survival associations across molecular data types. BMP6 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (9) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible BMP6 RNA expression–survival associations across cancer types. High BMP6 expression shows unfavorable associations in BLCA and ACC, but favorable associations in KIRC, SKCM, THCA and UCS. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for BMP6 RNA expression.
This table summarizes BMP6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 2. The strongest signals are observed in KIRC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for BMP6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. BMP6 shows lower tumor expression in KICH, KIRC, COAD, LUSC, KIRP and LUAD. The KICH box plot shows higher BMP6 RNA expression in normal versus tumor tissue (log2 FC = −4.355, t-test p < 0.001).
This table shows molecular features associated with BMP6 in patient tissues and cancer cell lines. In patient samples, BMP6 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, BMP6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and BLOOD_Leukemia.
